Tuveson, D., Rai, K. R. (June 2015) Augmenting NF-kappaB in poor-risk CLL: A general paradigm for other cancers? J Exp Med, 212 (6). pp. 830-1. ISSN 1540-9538 (Electronic)0022-1007 (Linking)
Preview |
PDF (Paper)
Tuveson J Exp Med 2014.pdf - Published Version Download (1MB) | Preview |
Abstract
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder of B lymphocytes. It has an extremely variable clinical course. Some patients have a rather indolent course, whereas others are known to have a rapidly progressive disease. Most patients die from causes related to CLL that can be due to bone marrow failure, infection, or transformation to a high-grade lymphoma. Clinical stratification of CLL has revealed that a subset of patients with poor prognosis harbor cytogenetic alterations and lack mutations at the immunoglobulin locus. Therefore, the development of additional molecular biomarkers for patients at high risk for early lethality from CLL could help direct their care toward enrollment in clinical trials of promising experimental approaches such as inhibitors of BCL2 or BCR signaling or CD19 chimeric antigen receptor T cells (which have been shown to eradicate CLL in patients who have failed other approaches). In this issue, Mansouri et al. report that somatic mutations in the NFKBIE gene occur in 7% of poor prognosis patients, and this may be a common mechanism contributing to disease progression by sustaining the survival of malignant CLL cells.
| Item Type: | Paper |
|---|---|
| Subjects: | diseases & disorders > cancer > cancer types > B cell lymphoma diseases & disorders > cancer > cancer types > leukemia |
| CSHL Authors: | |
| Communities: | CSHL labs > Tuveson lab |
| Depositing User: | Matt Covey |
| Date: | 1 June 2015 |
| Date Deposited: | 10 Jun 2015 18:54 |
| Last Modified: | 06 Nov 2017 20:20 |
| PMCID: | PMC4451126 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/31562 |
Actions (login required)
 |
Administrator's edit/view item |